| 1) Core items |
| Test code |
Test name |
Clinical description |
| C120 |
Cholesterol, High-Density Lipoprotein (HDL) |
Identification of cardiovascular protective factors |
| C121 |
Cholesterol, Low-Density Lipoprotein (LDL) |
Assessment of atherosclerotic risk |
| C119 |
Cholesterol, Total |
Assessment of dyslipidemia |
| C116 |
Creatinine |
Assessment of renal function and related complications |
| C180 |
Glucose [P] |
Assessment of concomitant diabetes |
| S490 |
Microalbumin [RU] |
Early assessment of kidney damage using microalbuminuria |
| C112 |
Potassium (K) [S] |
Evaluation of hypokalemic hypertension |
| W396 |
sdLDL cholesterol |
High specificity for atherosclerosis |
| C111 |
Sodium (Na) [S] |
Assessment of blood pressure changes due to fluid imbalance |
| C122 |
Triglycerides (TG) |
Assessment of the presence of metabolic syndrome |
| 2) Optional items |
| Test code |
Test name |
Clinical description |
| C106 |
Alanine Aminotransferase (ALT, GPT) |
Assessment of concomitant fatty liver disease |
| S525 |
Albumin [RU] |
Assessment of hypoalbuminemia |
| C105 |
Aspartate Aminotransferase (AST, GOT) |
Assessment of the presence of metabolic disorders |
| C117 |
Blood Urea Nitrogen (BUN) |
|
| S434 |
C-peptide [S] |
Indirect evaluation of insulin secretory capacity |
| C116 |
Creatinine |
|
| Z883 |
Cystatin-C |
Detailed assessment of renal function |
| Z883 |
Cystatin-C |
|
| C107 |
Gamma-Glutamyltransferase (GGT) |
Assessment of alcohol-related disorders |
| C123 |
Glucose [S] |
A basic indicator of diabetes |
| C431 |
HbA1c |
Diagnosis of diabetes and assessment of long-term glycemic control |
| E441 |
Insulin |
Assessment of insulin secretion and insulin resistance |
| S490 |
Microalbumin [RU] |
|
| W396 |
sdLDL cholesterol |
High specificity for atherosclerosis |
| E403 |
Thyroid Stimulating Hormone (TSH) |
Differential diagnosis of hypertension due to thyroid dysfunction |
| C118 |
Uric acid |
Evaluation of gout and metabolic diseases |
| 3) Supplementary items |
| Test code |
Test name |
Clinical description |
| E569 |
B-Type Natriuretic Peptide (BNP) |
|
| N596 |
Catecholamine, fractionated [24hU, LC-MS/MS] |
Screening for secondary hypertension due to pheochromocytoma and related conditions |
| GA0C |
Catecholamines 3 fraction [P] |
Screening for secondary hypertension due to pheochromocytoma and related conditions |
| L961 |
Cortisol, Free [24hU] |
Differential diagnosis of Cushing’s syndrome |
| C180 |
Glucose [P] |
Assessment of concomitant diabetes |
| GA0P |
Metanephrines, 2 fraction [24hU, LC-MS/MS] |
Screening for secondary hypertension due to pheochromocytoma and related conditions |
| S660 |
Metanephrines, fractionated, free [P, LC-MS/MS] |
Screening for secondary hypertension due to pheochromocytoma and related conditions |
| S805 |
NT-Pro BNP |
|
| N883 |
Renin activity [LC-MS/MS] |
Assessment of renin?aldosterone imbalance?related hypertension |
